1. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational Trial 
Toshitaka Morishima, MD, Hiroshi Ikai, MD, PhD, Yuichi Imanaka, MD, MPH, PhD 
Value in Health Regional Issues 
Volume 2, Issue 1, Pages (May 2013)
DOI: /j.vhri
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1 Markov model structure for economic evaluation of omalizumab.
Value in Health Regional Issues 2013 2, 29-36DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Tornado diagram summarizing one-way sensitivity analyses of the incremental cost-effectiveness ratio (cost per quality-adjusted life-year) of omalizumab plus standard therapy relative to standard therapy alone. RR indicates rate ratio for omalizumab plus standard therapy relative to standard therapy alone.
Value in Health Regional Issues 2013 2, 29-36DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Cost-effectiveness acceptability curve. This graph illustrates the probability that a treatment strategy is cost-effective over a range of willingness-to-pay thresholds for an additional quality-adjusted life-year.
Value in Health Regional Issues 2013 2, 29-36DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions